Navigation Links
Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
Date:10/27/2011

.

"If it was not for Dr. Chugani and his willingness to listen to us and help our son so quickly, Ben might not be flourishing the way he is today," Emily Kather said.  "Today, Ben is a typical – although we say exceptional in our eyes – two-year-old boy.  He is a joy and I am grateful every day that we found a knowledgeable and devoted pediatric neurologist when we did."

Dr. Chugani said, in accepting the award, "I am very humbled and honored to receive the IS Hero Award. Infantile Spasms is such a devastating, but treatable disorder that we (physicians) have to go that extra mile to make these children better.  What drives me is the emotional despair of the parents once they have read up on the disorder."

"I ask myself what I would do if I were in their situation.  We know that we don't always make the children better, but still, the parents know that we have tried, particularly if we make ourselves easily available to them and they know we are there for them.  I'd like to thank the Child Neurology Foundation for all of their efforts to increase awareness and understanding of infantile spasms.  I'd also like to thank Questcor Pharmaceuticals for the company's support for these initiatives and for their support of research into the underlying causes of IS."

Dr. Chugani will be honored at a special ceremony on Thursday, October 27, at the CNS Annual Meeting.  Emily Kather will be in attendance to introduce Dr. Chugani.    

Infantile Spasms

Infantile Spasms is a severe, ultra-rare form of epilepsy that affects infants, with onset typically occurring during the first year of life in about 90 percent of cases. IS incidence is estimated at approximately 2,000 new cases in the U.S. per year, which can be classified as an ultra-orphan disease. For comparison, orphan disease designation pertains to diseases that affect fewer than 200,000 people. IS patients experience
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Reports Third Quarter Financial Results
2. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
3. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
4. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
5. Questcor Provides Updated New Paid Prescription Trends
6. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
7. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
8. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
9. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
10. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
11. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)...   West Pharmaceutical Services, Inc. (NYSE: ... for injectable drug administration, announced today it plans to ... site in Waterford, Ireland . The ... cartridges and other high-value packaging components, in order to ... operational, this new site could bring approximately 150 new ...
(Date:10/1/2014)... , Oct. 1, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... into a definitive distribution agreement with Patterson Veterinary Supply. ... promote the full line of Abaxis veterinary products throughout ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, Inc. ... patented and proprietary technology used to develop and ... bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today ... from Abengoa Bioenergy for commercial scale production of ... into ethanol, developed under Abengoa,s license agreement with ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... a developer of Healthcare Technology Networks ("HTN") designed to ... today announces the launch of its proprietary Opioid Management ... United States Bone & Joint Decade , ... suffering from musculoskeletal disease filled 1.6 billion prescriptions. While ...
... SPRING, Md., April 6, 2012 Sunpeaks Ventures, ... "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution ... has entered into a sponsorship agreement ("Agreement") with a ... Clotamin, including advertising, media, and promotional elements. The Agreement ...
Cached Medicine Technology:Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 3
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, Oct. ... the roses -- literally -- may face an increased risk of ... a study of over 3,000 older Americans, researchers found those who ... were more than three times as likely to die in the ... In fact, anosmia -- the inability to distinguish odors -- ...
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
(Date:10/1/2014)... the adage that encourages people to keep their "eyes ... comes to exercise. When walking, staying focused on a ... appear shorter and help people walk there faster, psychology ... to walking while looking around the environment naturally, offers ... , "People are less interested in exercise if physical ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... novel study found that the use of Herceptin in advanced ... toxicity − nearly 28 percent of patients treated with ... lining is that much of the damage to the heart ... published online August 14 in the Journal of Clinical Oncology, ...
... OHSU Tinnitus Clinic and the School of Dentistry is ... their relationship with hearing loss//. Apparently the relationship has ... of the study leaders, said"Over the years, we have ... convinced that long-term exposure to sound from high-speed hand ...
... The three-hour open-heart surgery was performed on a 17 yr ... ,An eight-member team led by cardio thoracic surgeon ... suffering from an arterial septal, congenital defect on the 4th ... of TMCH said that the patient, S.Velumurugan's condition was stable ...
... from the US have shown that yellow plant pigments ... macular degeneration (AMD). ,The study conducted by the ... published in the Journal of Ophthalmology, states that carrots ... but brightly coloured yellow and green vegetables do have ...
... Most women who undergo surgery following an early pregnancy ... under general ,anesthesia//. However a new study has raised ... ,Early pregnancy failure - or EPF - occurs in ... with surgery typically haven't been performed in ,an office-based ...
... of a fourth drug to the usual three-drug HIV treatment ... did not reduce the HIV load// or the drug resistance, ... 16 issue of JAMA, a theme issue on HIV/AIDS. ... of Cornell University, New York, presented the findings of the ...
Cached Medicine News:Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 2Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 3Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 2Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 3Health News:Yellow Fruits And Vegetables Help In Fight Against Loss Of Eyesight 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 3Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
Medicine Products: